December 9, 2021 Newsletter

This time of year we are reminded of the gifts of Gold, Frankincense, and Myrrh – gifts fit for a king! There are actually medically beneficial properties to both Frankincense and Myrrh.

The Boswellia serrata exudate or gum (known in India as “guggulu”) that forms an aromatic resin traditionally used as incense – and known as frankincense (especially when retrieved from Boswellia species found in Eritrea and Somalia but also from the Indian variety) – has been considered for thousands of years to possess therapeutic properties. It is used in Ayurvedic medicine, as well as in traditional medicine in China and the Middle East, particularly for its anti-inflammatory effects to treat chronic conditions. In fact, such essential oils have been used since 2800 BC to treat various inflammatory conditions, including skin sores and wounds, as well as in perfumes and incense. In the West, use of frankincense dates back to thousands of years as well, more often found in the form of incense for religious and cultural ceremonies.Over the past 2 decades, evidence supporting the use of frankincense for therapeutic medical purposes has increased, particularly because of its purported anti-inflammatory and anticancer properties.

Terpenoids and essential oils are the primary components of frankincense and are known to impart anti-inflammatory and anticancer activity. The same is true for myrrh, which has been combined with frankincense in traditional Chinese medicine as a single medication for millennia, with the two acting synergistically and considered still to be a potent combination in conferring various biological benefits.

In 2010, in a systematic review of the anti-inflammatory and anticancer activities of Boswellia species and their chemical ingredients, Efferth and Oesch found that frankincense blocks the production of leukotrienes, cyclooxygenase (COX) 1 and 2, as well as 5-lipoxygenase; and oxidative stress. It also contributes to regulation of immune cells from the innate and acquired immune systems and exerts anticancer activity by influencing signaling transduction responsible for cell cycle arrest, as well as inhibition of proliferation, angiogenesis, invasion, and metastasis. The investigators also reported on clinical trial results that have found efficacy of frankincense and its constituents in ameliorating symptoms of psoriasis and erythematous eczema, among other disorders.

Another study completed in 2016 sought to identify the active ingredients responsible for the anti-inflammatory and analgesic effects of frankincense. They found that alpha-pinene, linalool, and 1-octanol were key contributors. These constituents were noted for suppressing COX-2 overexpression in mice, as well as nociceptive stimulus-induced inflammatory infiltrates.

A 2017 study evaluated the biological activities of the essential oil in pre-inflamed human dermal fibroblasts using 17 key protein biomarkers. Frankincense essential oil displayed significant antiproliferative activity and suppressed collagen III, interferon gamma-induced protein 10, and intracellular adhesion molecule 1. The investigators referred to the overall encouraging potential of frankincense essential oil to exert influence over inflammation and tissue remodeling in human skin and called for additional research into its mechanisms of action and active constituents.

The main active ingredient in frankincense, boswellic acid, has been shown to promote apoptosis, suppress matrix metalloproteinase secretion, and hinder migration in metastatic melanoma cell lines in mice. A 2019 study. demonstrated that frankincense essential oil yielded substantial antimelanoma activity in vitro and in vivo and ameliorated hepatotoxicity caused by acetaminophen.

The use of frankincense in traditional medicine has a long and impressive track record. Recent research provides reason for optimism, and further investigating the possible incorporation of this botanical agent into modern dermatologic therapies appears warranted. Clearly, however, much more research is needed.


August 30, 2021 Newsletter

Summer temperatures and summer activities require good care of your skin. Proper and frequent use of broad spectrum sunscreens is essential for protection for your skin from harmful UV rays and from burns and potential sunburn pain. While using sunscreens you should be aware that a number of Neutrogena and Aveeno products have been voluntarily recalled by their manufacturer. These companies recently pulled several sunscreens from market shelves after independent testing had found they were contaminated with a cancer-causing chemical called benzene. The National Cancer Institute has stated that exposure to benzene increases the risk of developing leukemia and other blood disorders. CVS Health also stopped selling two of its after-sun care products due to similar findings.

The vast majority of tested sunscreens, however, were free of benzene, and experts stress the importance of sunscreen use to protect skin from the aging and cancerous effects of the sun.

All batches, or lots, of these four Neutrogena spray sunscreens and one Aveeno spray were voluntarily recalled this week by parent company Johnson & Johnson (J&J) “out of an abundance of caution”:

Neutrogena® Beach Defense® aerosol
Neutrogena® Cool Dry Sport aerosol
Neutrogena® Invisible Daily™ defense aerosol
Neutrogena® Ultra Sheer® aerosol
Aveeno® Protect + Refresh aerosol

Benzene is not an ingredient in any of these sunscreen products, but it was detected in some samples of the impacted aerosol sunscreen finished products. The manufacturer of these products is recommending that consumers should stop using these specific products and appropriately discard them.

Specific lots of all recalled Neutrogena and Aveeno sunscreens can be found here , and customers can call with questions and request a refund by completing this form, or calling 1-800-458-1673.

CVS also stopped selling CVS Health After Sun Aloe Vera and CVS Health After Sun Aloe Vera Spray a day after the Johnson & Johnson recall was announced. CVS Health’s corporate communications, told CNN the company is “cooperating with Johnson & Johnson’s voluntary recall.”

“CVS products have not been recalled,” but the company has paused sales of the two CVS products, which tested positive for benzene, “out of an abundance of caution.” CVS Health is working with the supplier of the products to “take appropriate additional steps.”

Why were the sunscreens recalled?
The voluntary recalls and pause in sales came after an independent lab tested 294 samples from 69 brands of sprays, lotions, gels and creams designed to protect the skin from the sun or care for the skin after sun. Of those, 78 samples tested positive for benzene.

Contamination appeared in specific batches of sunscreen, rather than a specific brand, said David Light, CEO and founder of Valisure, the independent lab that ran the tests. “The finding of benzene in sunscreen was certainly surprising to me as a scientist and a consumer. I’m quite a heavy user of sunscreen myself; I have five kids and we all use sunscreen, so it was rather concerning to find such high levels,” Light said.

Multiple samples contained “significantly detectable benzene and some batches contained up to 3.1 times the conditionally restricted limit,” according to the citizen petition asking for action that Valisure filed with the US Food and Drug Administration. “We petitioned the FDA to recall or to request recalls of the products that are 0.1 per million and above,” Light told CNN. “It’s obvious that we shouldn’t be taking that risk, and we just wanted it cleaned up.”

Samples of three of the recalled Neutrogena spray sunscreens — Beach Defense, Invisible Daily and Ultra Sheer — and one CVS brand — After-sun Aloe Vera Soothing Spray — had levels of benzene that were 2 parts per million or higher, according to Valisure’s tests. Another spray, Neutrogena’s Cool Dry Sport, and CVS Health’s After-sun Aloe Vera Moisturizing Gel, tested at .01 to 2 parts per million of benzene in some samples. Aveeno’s Protect + Refresh aerosol, which was the fifth sunscreen recalled by J&J, was not tested by Valisure.

Samples of three Banana Boat products also contained levels of benzene at those levels: Kids Max Protect & Play Sunscreen C-Spray SPF 100, UltraMist Deep Tanning Dry Oil Continuous Clear Spray SPF 4 and Ultra Sport Clear Sunscreen Spray SPF 100.

The sunscreens tested by Valisure were only a tiny sample of the more than 11,000 registered sun care products on the market. The Personal Care Products Council, an industry association, said its members were “firmly committed” to providing products with “ingredients that have been thoroughly tested for safety and follow the requirements of the law.” “We are aware of the study reporting the presence of benzene in some of the sunscreen products tested,” the council said in a statement. “There is nothing more important than safety. If our consumers can’t believe in a product or rely on it to do what it says, then nothing else matters.”

What is benzene?
Benzene is a natural component of crude oil, gasoline and cigarette smoke and ranks in the top 20 chemicals used for production of “lubricants, rubbers, dyes, detergents, drugs, and pesticides,” as well as “plastics, resins, and nylon and synthetic fibers,” according to the US Centers for Disease Control and Prevention.
At room temperature, benzene is a colorless or light yellow liquid with a sweet odor. Highly flammable, it will float on water, and while it evaporates quickly, it is heavier than air and can sink into low-lying areas, the CDC noted.

Gas emissions from volcanoes and forest fires are natural sources of benzene, but the largest sources are emissions from burning coal and oil, motor vehicle exhaust, and evaporation from gasoline service stations, according to the Agency for Toxic Substances and Disease Registry (ATSDR).

Exposure to high levels of benzene in the air can cause death, the ATSDR says, but the impacts of eating foods or drinking liquids containing lower levels of benzene are not known. “If you spill benzene on your skin, it may cause redness and sores. Benzene in your eyes may cause general irritation and damage to your cornea,” the ATSDR said.

Cigarette smoke and off-gassing from furniture wax, detergents, glue and paint are sources of indoor exposure to benzene, according to the CDC, while outdoor air can be polluted with benzene from “gas stations, motor vehicle exhaust, and industrial emissions.”

How did benzene get into sunscreens?
No one knows for sure how the toxin ended up in sun care products. Benzene was not an ingredient in any of the sunscreens, so experts suspect contamination had to have occurred during the manufacturing process.
“There are a lot of theories,” said Scott Faber, the senior vice president of government affairs for the Environmental Working Group (EWG), a non-profit consumer health advocacy group which puts out a yearly guide to safe sunscreens.

“Benzene could be a byproduct of the process of making the chemicals that companies sell to the formulators of personal care products and sunscreens. Or it could be that some of those chemicals break down into benzene, although that seems less likely,” Faber said.
“But it’s very alarming, especially since the FDA does not require companies to test ingredients for contaminants, nor does it require testing for such chemicals at a finished product stage,” he added.

What is the FDA doing?
In response to Valisure’s petition, the FDA told CNN that it “evaluates and assesses the information provided in citizen petitions of this type and, generally, initiates an independent testing and verification process.”
“While the FDA evaluates the citizen petition submitted by Valisure, we will continue to monitor sunscreen manufacturing and marketing to help ensure the availability of safe sunscreens for U.S. consumers,” an FDA spokesperson said.

Benzene is not the only concern when it comes to sunscreen. A number of sunscreens have been shown to be ineffective or contain chemicals that can enter the bloodstream and disrupt hormones. In EWG’s 2021 guide to sunscreens, they analyzed over 1,800 products and found that 75% did not provide adequate sun protection — or included ingredients linked to harm. Still, there were over 200 products that did meet their safety standards.

All of this uncertainty may leave consumers unsure of what to do, and experts worry some may forgo the use of sunscreen altogether. But, experts warned, that’s an even worse idea. Melanoma, one of the most deadly forms of skin cancer, has been on the rise globally for decades. And while survival rates are getting better, melanoma is still the fifth most commonly diagnosed cancer in the United States.

And of course, it’s always a great choice to use common sense practices as well to protect your skin from harmful rays. Wear shorts, shirts, pants and hats to help block dangerous rays and apply safe sunscreens to exposed skin. Wisely choose your time in the sun by avoiding the most intense rays between 10 a.m. and 4 p.m. and seek shade whenever possible.

Dr. Angela Moore and Arlington Center for Dermatology offer a number of safe, Benzene-FREE, sunscreens that are just right for you and your family. Ask your provider about which sunscreen would be best for you.
Source: CNN July 17, 2021 Sandee LaMotte


June 29, 2021 Cosmetic Specials

AlphaRet Chemical Peel One Day Event

Tuesday July 20, 2021.

AlphaRet Chemical Peel $100 ($150 value).

By Appointment only.  Call 817-795-7546 ext. 304 to RSVP.

**The Skinbetter Representative will be here from 9:30 – 11:30 am if you would like to speak with her**

Purchase one (1) SkinBetter chemical peel for $100. Normally $150. Requires $50 deposit to save your spot.

Purchase a package of three (3) SkinBetter chemical peels for $399. Normally $450. Requires $200 deposit to save your spot.

Purchase a package of six (6) Skin Better chemical peels for $750. Normally $900. Also included in the package is travel sizes of SkinBetter Alpharet ($28 value) and SkinBetter Alto ($33 value). AND…something special – a VIP Grab Bag! Requires $300 deposit to save your spot


March 5, 2021 Clinical Trials

NEW study for ages 9 years and older. 3-week oral antibiotic study for back and/or chest acne. At least 20 lesions are required. Photographs will be taken.

How can you participate?

Inquire about how you can participate in this study today.

TO LEARN MORE ABOUT THE ACNE STUDY, CONTACT: or call 817-795-7546 ext. 339


March 5, 2021 Clinical Trials

NEW study for adults 18 years and older with a diagnosis of psoriasis. Must have history of at least 6 months on Consyntex or Talz. No prior use of Skyrizi. No investigational drug use within 30 days. No major surgeries within 12 weeks, or major planned surgeries. You are being asked whether you would like to voluntarily participate in a research study of a drug called risankizumab (SkyriziTM).

This research study involves the use of an approved drug called risankizumab (SkyriziTM) to treat moderate to severe psoriasis. This study is being run in approximately 50 research centers in 9 countries and is expected to enroll approximately 250 subjects.

If you decide to participate, you will be in this study for up to 64 weeks. The study comprises 3 periods: There will be a 30-day Screening Period, a 52-week open-label study period and a 20-week follow-up period following the last dose of study drug scheduled at Week 40 visit (weeks 40-52 of the open-label period will also be weeks 1-12 of the follow-up period). The open-label period means that you, your study doctor and AbbVie know that what study treatment you are receiving.

You may need to come in for additional (unscheduled) visits if necessary, as determined by your study doctor. If you are eligible to receive study treatment, you will receive 2 injections of active risankizumab 75 mg (150 mg total dosage) subcutaneously (SC) at Weeks 0 and 4 visits, and then every 12 weeks (q12w) until the last dose at Week 40 visit. At any time, you may choose to discontinue from the study and end study participation early, or your study doctor may discontinue your participation for any reason at any time.

AbbVie is sponsoring this study. Being in this study does not replace your regular medical care. AbbVie may stop this study prematurely, either in its entirety or at any study site, for reasonable cause, provided that written notice is submitted in advance of the intended study stop.


March 5, 2021 Clinical Trials

Arlington Research Center is looking for children and adults, aged 6 years and up who have eczema, to participate in a clinical research study evaluating an investigational cream. This study includes up to 5 visits for 2 months.

Studies for youth and adults. Must have a history of atopic for at least 3 months for youth 6-17 years of age, and for at least 6 months for adults 18 years and older. Study patients previously on the ARQ-151 are excluded.

How can you participate?

Inquire about how you can participate in this study today.



March 5, 2021 Clinical Trials

NEW study for adults 18 and older. Topical cream and at-home phototherapy system. Must have facial vitiligo. Subjects with vitiligo on the hands, forearms, or elbows may treat areas in addition to the face with the cream. Begins in mid-March.

How can you participate?

Inquire about how you can participate in this study today.

TO LEARN MORE ABOUT THE VITILIGO STUDY, CONTACT: or call 817-795-7546 ext. 339


January 25, 2021 Newsletter

Hidradenitis suppurativa (HS) is a little-known disease that causes deep and painful lumps under the skin, usually in the armpits or groin.

Many people mistake the deep lumps for painful pimples or acne cysts. HS can also be misdiagnosed as boils, infected hair follicles (folliculitis), or a sexually transmitted disease.

Because HS is often mistaken for another condition, people can go years without getting the care they need. Some people live with HS for 12 years or longer before getting diagnosed.

Without the right diagnosis and individualized treatment, HS can worsen. What starts out as one or two deep, painful, pimple-like lumps can turn into several lumps. In time, these lumps can break open and leak a foul-smelling liquid. The lumps can continue to return, rupture, and heal.

Patients with hidradenitis suppurativa have a high prevalence of acne vulgaris, research published in Journal of the American Academy of Dermatology shows. Furthermore, the mean age of onset of hidradenitis suppurativa patients is lower when they also have acne vulgaris, the data show.

The prevalence of acne vulgaris was assessed in consecutive new patients with hidradenitis suppurativa referred to the Department of Dermatology at Bispebjerg Hospital in Copenhagen, Denmark.

A total of 302 patients (191 women and 111 men) with a mean age of 39.4 years referred between January 1, 2016 and October 8, 2018 were included in the evaluation.

The overall prevalence of acne vulgaris was 21.2%. Nineteen of the patients with acne vulgaris (29.7%) had hidradenitis suppurativa assessed as Hurley stage I, 39 (60.9%) Hurley stage II and 6 (9.4%) Hurley III. There was no statistical difference in Hurley stage of hidradenitis suppurativa between patients with and without acne.

However, acne vulgaris was associated with a lower age of onset of hidradenitis suppurativa. Those patients with hidradenitis suppurativa and acne vulgaris attending the clinic were significantly younger than those without acne vulgaris (33.8 versus 40.8 years,), and the mean age at onset of hidradenitis suppurativa was significantly lower in patients with acne vulgaris than it was in those without (21.4 versus 27.2 years).

Hidradenitis suppurativa patients with acne vulgaris also had lower levels of plasma inflammatory markers (C-reactive protein [CRP], neutrophils, and neutrophil/lymphocyte ratio [NLR]) than those without acne vulgaris.

Prevalence of acne vulgaris among hidradenitis suppurativa patients was not impacted by the sex of the patient, smoking status, obesity or diagnosis of polycystic ovary syndrome (PCOS). There was also no difference in Dermatology Quality of Life Index (DLQI) and localization of hidradenitis suppurativa between the patients with and without acne vulgaris.

Patients referred for specialized hospital care tended to have a high prevalence of acne vulgaris. Furthermore, hidradenitis suppurativa patients with acne vulgaris tend to have a significantly lower mean age and age at onset of hidradenitis suppurativa compared to hidradenitis suppurativa patients without acne vulgaris. These findings call for greater awareness of this association between acne and HS and for a co-management approach to treatment.

The Danish findings support those of a population-based sample from the United states which found that the prevalence of acne vulgaris was 15.2% among adults with hidradenitis suppurativa, compared to 2.9% in adults without hidradenitis suppurativa.

The US cross-sectional analysis used electronic health records data from a population-based sample of over 55 million patients to identifying adults with acne vulgaris among patients with and without hidradenitis suppurativa.

Prevalence of acne vulgaris in patients with hidradenitis suppurativa was found to be 15.2% (7,315 /48,050), compared to 2.9% (497,360 /16,899,470) for adults without hidradenitis suppurativa. Prevalence of acne vulgaris was greatest among hidradenitis suppurativa patients who were female (16.4%), aged 18-44 years (18.2%), non-white (17.5%), obese (15.5%), and had PCOS (28.7%).

Hidradenitis suppurativa patients had 4.51 times the odds of having acne vulgaris compared to non-HS patients, and the association between hidradenitis suppurativa and acne vulgaris was generally stronger for patients who were male, aged ≥ 65 years, non-whites, and obese.

The association between acne vulgaris and polycystic ovary syndrome (PCOS) is already well established. Recent research has demonstrated that approximately 1 in 11 women with hidradenitis suppurativa also have PCOS. The link among the three conditions is not yet clearly established, as circulating and end organ androgen expression appear to be normal among hidradenitis suppurativa patients.

If you have signs of HS or acne, have your dermatologist examine for both as HS may not be easily recognized by the general public. Dr. Moore’s research team, Arlington Research Center, his screening patients for HS to participate in clinical trials for HS. We also have clinical trials for acne. Contact Arlington Research Center at or 817-795-7546 ext. 339 to see if you qualify for an HS clinical trial.

Sources: and Dermatology News February 2019


December 30, 2020 Clinical Trials

If your child has severe eczema, learn how he or she could participate in this research study of an oral study drug for children 6 months to 11 years of age.

The purpose of this study is to examine how the body processes the study drug, evaluate drug safety and assess how the safety and taste hold up (tolerability and palatability) in children (6 months to 11 years old) with severe atopic dermatitis, also known as eczema. The study medication comes in a tablet form or a solution that will be taken by mouth.

Your child may qualify for this research study, if the following applies to your child:

  • Your child is between 6 months to 11 years old
  • Your child has severe Atopic Dermatitis
  • Your child is experiencing active Atopic Dermatitis symptoms, such as: itchiness, irritated dry skin, redness, etc.

You may receive reimbursement for your time and travel expenses related to study participation.
Please visit for locations participating in the study.


December 30, 2020 Clinical Trials

While severe psoriasis affects the skin, causing it to itch and burn, it can also have an emotional impact on adolescents, as well as their parents.

Because of the raised, red, scaly patches on their skin, many adolescents feel ashamed or embarrassed by their condition. These emotions can cause them to not want to hang out with friends, attend school functions, or participate in extracurricular activities.

For parents watching these physical and emotional effects, it’s difficult when other treatments have not been successful in managing their child’s psoriasis.

Because many adolescents and their families struggle with psoriasis, this research study is being conducted to evaluate an investigational drug for severe psoriasis. In this study, researchers want to learn more about the safety and effectiveness of the investigational drug.

The investigational drug has not been approved by any regulatory agency for the treatment of children and adolescents with this condition. It is only available to children and adolescents in research studies like this one.

The results of this study will provide more information about the investigational drug and whether it could one day be approved for children and adolescents with severe plaque psoriasis.

What will happen during this study?

To participate in this study, all patients will go through a screening process to determine if they are eligible. If a patient meets the study requirements, agrees to participation, and has their parents’ permission, they will begin the study.

Patients will receive five subcutaneous injections (needle inserted just beneath the skin) of the investigational drug over the course of 40 weeks. All injections will be given at the study clinic.

Total participation in this study will last up to 65 weeks, which includes approximately 9 study clinic visits for injections of the investigational drug, blood tests, and other assessments, as well as 1 follow-up phone call. Patients who complete participation in this study may be able to take part in a 52-week extension study in which all patients will continue receiving the investigational drug.

What are the benefits and risks related to this study?

It’s possible patients could benefit from study participation, but that is not guaranteed. However, participation in this study may benefit children and adolescents with plaque psoriasis in the future.

Patients could also experience one or more side effects. Before beginning the study, the study staff will review all study-related risks and side effects with parents and patients.

Throughout their study participation, patients will be monitored closely. The sponsor of this study was required to design a protocol, which explains all study procedures. An independent review board responsible for patient safety reviewed this protocol, approved it, and requires that
it be followed exactly as written.

Who is eligible to participate in this study?
To be eligible for this study, patients must:

  • Be 12 to 17 years of age
  • Have been diagnosed with chronic plaque psoriasis for at least 6 months

All study-related visits, tests, and drugs will be provided at no cost. In addition, compensation for study-related travel may be provided.

Copyright © 2020 . All rights reserved. Website Designed by Gott Marketing